Drug Profile
BMS 986142
Alternative Names: BMS-986142Latest Information Update: 05 Mar 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis; Sjogren's syndrome
Most Recent Events
- 05 Mar 2021 No development reported - Phase-II for Rheumatoid arthritis (Treatment-experienced) in USA, Canada, Canada, Mexico, Spain, Austria, Japan, Russia, South Africa, Belgium, Taiwan, Argentina, Brazil, Chile, Colombia, Czech Republic, France, Germany, Israel, Italy, Netherlands, Poland, South Korea (PO)
- 05 Mar 2021 No development reported - Phase-II for Sjogren's syndrome in USA, Puerto Rico, Australia, Chile, Colombia, Italy, Mexico, Peru, Poland, Russia, South Africa (PO)
- 07 Jun 2018 Bristol-Myers Squibb completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in Argentina, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, France, Germany, Israel, Italy, Japan, Mexico, Netherlands, Poland, Russia, South Africa, South Korea, Spain, Taiwan, USA (PO) (NCT02638948) (EudraCT2015-002887-17)